15 Nov Still No Iluvien
Alimera Sciences suffers set back with Iluvien. In a complete response letter to the company, the FDA did not approve the device for diabetic retinopathy citing concerns over safety....
Alimera Sciences suffers set back with Iluvien. In a complete response letter to the company, the FDA did not approve the device for diabetic retinopathy citing concerns over safety....
The American Academy of Ophthalmology starts this week. I will be going to learn about the latest in retinal disease, but also will be teaching...
Iluvien, a sustained release intraocular drug delivery system, may get closer to FDA approval. The parent company just submitted additional safety/efficacy data as requested by the FDA....
Iluvien, a promising sustained drug delivery system for the treatment of diabetic macular edema, fails to pass FDA scrutiny...
Retinal specialists have been using intravitreal injections to treat retinal disease. Sustained release systems are gaining in popularity. Soon, more than retinal disease will be treated with these devices....
Iluvien is a type of drug delivery system that may be FDA approved for treating diabetic retinopathy. Instead of laser treatment, the eye will be injected....
Alimera's Iluvien proving effective in phase 3 clinical trials. Iluvien will release fluocinolone acetonide for the treatment of diabetic macular edema. Iluvien is an injectable extended release delivery system....
Intraocular drug delivery systems are developing to treat diabetic macular edema. Sustained release systems offer hope of long term treatment, compliance and little or no side effects....